CDK 4/6 inhibitors for metastatic breast cancer
CDK 4/6 inhibitors for metastatic breast cancer
IMW 2017 highlights
Outcome of third salvage autologous stem cell transplantation in multiple myeloma
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma
Long term effects of myeloma treatment
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma
Caring for multiple myeloma carers
Impact of recurrent myeloma alterations on drug response
What is the biology behind immunotherapy for MM?
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma
Is precision myeloma medicine more hype than reality?
Asia-Pacific approaches to myeloma trials